Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 114

1.

Variability in Trough Total and Unbound Teicoplanin Concentrations and Achievement of Therapeutic Drug Monitoring Targets in Adult Patients with Hematological Malignancy.

Byrne CJ, Roberts JA, McWhinney B, Fennell JP, O'Byrne P, Deasy E, Egan S, Desmond R, Enright H, Ryder SA, D'Arcy DM, McHugh J.

Antimicrob Agents Chemother. 2017 May 24;61(6). pii: e02466-16. doi: 10.1128/AAC.02466-16. Print 2017 Jun.

2.

Population pharmacokinetics of total and unbound teicoplanin concentrations and dosing simulations in patients with haematological malignancy.

Byrne CJ, Parton T, McWhinney B, Fennell JP, O'Byrne P, Deasy E, Egan S, Enright H, Desmond R, Ryder SA, D'Arcy DM, McHugh J, Roberts JA.

J Antimicrob Chemother. 2018 Apr 1;73(4):995-1003. doi: 10.1093/jac/dkx473.

PMID:
29272419
3.

Teicoplanin use in adult patients with haematological malignancy: Exploring relationships between dose, trough concentrations, efficacy and nephrotoxicity.

Byrne CJ, Egan S, Fennell JP, O'Byrne P, Enright H, Deasy E, Ryder SA, D'Arcy DM, McHugh J.

Int J Antimicrob Agents. 2015 Oct;46(4):406-12. doi: 10.1016/j.ijantimicag.2015.05.019. Epub 2015 Jul 2.

PMID:
26228465
4.

Population pharmacokinetics of teicoplanin and attainment of pharmacokinetic/pharmacodynamic targets in adult patients with haematological malignancy.

Byrne CJ, Roberts JA, McWhinney B, Ryder SA, Fennell JP, O'Byrne P, Deasy E, Egan S, Desmond R, Enright H, D'Arcy DM, McHugh J.

Clin Microbiol Infect. 2017 Sep;23(9):674.e7-674.e13. doi: 10.1016/j.cmi.2017.02.032. Epub 2017 Mar 6.

5.

Randomized comparison of serum teicoplanin concentrations following daily or alternate daily dosing in healthy adults.

Rouveix B, Jehl F, Drugeon H, Brumpt I, Caulin E.

Antimicrob Agents Chemother. 2004 Jul;48(7):2394-9.

6.

Loading dose required to achieve rapid therapeutic teicoplanin trough plasma concentration in patients with multidrug-resistant gram-positive infections.

Wang JT, Liao HI, Wu Lin FL, Chang SC.

Basic Clin Pharmacol Toxicol. 2012 May;110(5):416-20. doi: 10.1111/j.1742-7843.2012.00862.x. Epub 2012 Feb 28.

7.

Variability in protein binding of teicoplanin and achievement of therapeutic drug monitoring targets in critically ill patients: lessons from the DALI Study.

Roberts JA, Stove V, De Waele JJ, Sipinkoski B, McWhinney B, Ungerer JP, Akova M, Bassetti M, Dimopoulos G, Kaukonen KM, Koulenti D, Martin C, Montravers P, Rello J, Rhodes A, Starr T, Wallis SC, Lipman J; DALI Study Authors.

Int J Antimicrob Agents. 2014 May;43(5):423-30. doi: 10.1016/j.ijantimicag.2014.01.023. Epub 2014 Feb 22.

PMID:
24630304
8.

Optimal Trough Concentration of Teicoplanin in Febrile Neutropenic Patients with Hematological Malignancy.

Sato Y, Hiramatsu K, Suzuki Y, Tanaka R, Kaneko T, Nonoshita K, Ogata M, Kadota JI, Itoh H.

Chemotherapy. 2018;63(1):29-34. doi: 10.1159/000481725. Epub 2017 Nov 24.

PMID:
29169153
9.

Teicoplanin therapeutic drug monitoring in critically ill patients: a retrospective study emphasizing the importance of a loading dose.

Pea F, Brollo L, Viale P, Pavan F, Furlanut M.

J Antimicrob Chemother. 2003 Apr;51(4):971-5. Epub 2003 Feb 25.

PMID:
12654757
10.

Population pharmacokinetic and pharmacodynamic analyses of teicoplanin in Japanese patients with systemic MRSA infection.

Ogawa R, Kobayashi S, Sasaki Y, Makimura M, Echizen H.

Int J Clin Pharmacol Ther. 2013 May;51(5):357-66. doi: 10.5414/CP201739.

PMID:
23458228
11.

Variability in teicoplanin protein binding and its prediction using serum albumin concentrations.

Yano R, Nakamura T, Tsukamoto H, Igarashi T, Goto N, Wakiya Y, Masada M.

Ther Drug Monit. 2007 Aug;29(4):399-403.

PMID:
17667792
12.

Recommended initial loading dose of teicoplanin, established by therapeutic drug monitoring, and outcome in terms of optimal trough level.

Sato M, Chida K, Suda T, Muramatsu H, Suzuki Y, Hashimoto H, Gemma H, Nakamura H.

J Infect Chemother. 2006 Aug;12(4):185-9.

PMID:
16944256
13.

Population pharmacokinetics of teicoplanin in children.

Ramos-Martín V, Paulus S, Siner S, Scott E, Padmore K, Newland P, Drew RJ, Felton TW, Docobo-Pérez F, Pizer B, Pea F, Peak M, Turner MA, Beresford MW, Hope WW.

Antimicrob Agents Chemother. 2014 Nov;58(11):6920-7. doi: 10.1128/AAC.03685-14. Epub 2014 Sep 15.

14.

Measurement of Teicoplanin Concentration With Liquid Chromatography-Tandem Mass Spectrometry Method Demonstrates the Usefulness of Therapeutic Drug Monitoring in Hematologic Patient Populations.

Chae H, Lee JJ, Cha K, Her SH, Kim HY, Han E, Kim M, Kim Y, Cho SY, Lee DG.

Ther Drug Monit. 2018 Jun;40(3):330-336. doi: 10.1097/FTD.0000000000000498.

PMID:
29746433
15.

Population pharmacokinetics and dosing optimization of teicoplanin in children with malignant haematological disease.

Zhao W, Zhang D, Storme T, Baruchel A, Declèves X, Jacqz-Aigrain E.

Br J Clin Pharmacol. 2015 Nov;80(5):1197-207. doi: 10.1111/bcp.12710. Epub 2015 Sep 5.

16.

Albumin concentration significantly impacts on free teicoplanin plasma concentrations in non-critically ill patients with chronic bone sepsis.

Brink AJ, Richards GA, Lautenbach EE, Rapeport N, Schillack V, van Niekerk L, Lipman J, Roberts JA.

Int J Antimicrob Agents. 2015 Jun;45(6):647-51. doi: 10.1016/j.ijantimicag.2015.01.015. Epub 2015 Mar 6.

PMID:
25819167
17.

Comparison of pharmacokinetics of individual teicoplanin components in patients.

Hanada K, Ikari S, Koukaki Y, Utena A, Kimura T, Hamano K, Ariki H, Masuhara K, Ogata H.

Biol Pharm Bull. 2007 May;30(5):952-4.

18.

Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration
.

Takechi K, Yanagawa H, Zamami Y, Ishizawa K, Tanaka A, Araki H.

Int J Clin Pharmacol Ther. 2017 Aug;55(8):672-677. doi: 10.5414/CP203009.

PMID:
28655381
19.

Evaluation of teicoplanin concentrations and safety analysis in neonates.

Yamada T, Kubota T, Nakamura M, Ochiai M, Yonezawa M, Yano T, Kawashiri T, Egashira N, Hara T, Masuda S.

Int J Antimicrob Agents. 2014 Nov;44(5):458-62. doi: 10.1016/j.ijantimicag.2014.07.005. Epub 2014 Aug 20.

PMID:
25218156
20.

Therapeutic Drug Monitoring of Teicoplanin in Haematological Malignancy Patients with Febrile Neutropenia and Optimizing Dosage Regimens.

Hu S, Wang T, You H, Wei S, Song H, Zhang T, Zhang D, Dong Y.

Basic Clin Pharmacol Toxicol. 2018 Nov;123(5):594-601. doi: 10.1111/bcpt.13029. Epub 2018 Jun 13.

PMID:
29702731

Supplemental Content

Support Center